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The small interfering RNA (siRNA)-mediated target mRNA cleavage activity generates cleaved mRNA
fragments with varied termini, which creates major technical challenges for the accurate and efﬁcient
detection and veriﬁcation of cleavage sites on target mRNAs. Here we used a sensitive stem-loop array
reverse transcription polymerase chain reaction (SLA-RT-PCR) approach to detect and verify the siRNA-
mediated target mRNA cleavage sites by determining precise sequences at the 3′- termini of cleaved
mRNA fragments in human cells under physiological conditions. Our results demonstrated the great
potential and broad applications of using the SLA-RT-PCR as a sensitive, cost-efﬁcient, and high-
throughput tool to systematically detect siRNA-targeted mRNA cleavage sites and fragments in human
cells.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The ability of short-interfering RNA (siRNA) to silence the activity
of speciﬁc genes has been proved to be very useful in dissecting
genetic function [1]. The siRNA also holds considerable promise as a
novel therapeutic approach to silence disease-causing genes, parti-
cularly those encoding socalled ‘non-druggable’ targets that are not
amenable to conventional therapeutics such as small molecules,
proteins, or monoclonal antibodies [2,3]. However, the major ob-
stacles to efﬁciently knock-down gene expression in vivo and use
siRNAs to silence the pathogenic genes in clinical practice by RNAi
technologies are the systemic delivery of therapeutic siRNAs [3–5],
their off-target effects [2,6], and the lack of accurate and efﬁcient
methods and techniques in detection of target mRNA intermediates
and end-products resulted from siRNA activities [7,8].
It has been shown that mammalian siRNAs repress gene ex-
pression by cleaving target mRNAs and leading to the sequential
degradation through RNA-induced silencing complex (RISC) [9,10].
The siRNA cleavage site on the mRNA target is usually located in the
middle of the region spanned the siRNA:target duplex [11]. Several
reports recently suggested that the efﬁcacy of RNAi
observed in vivo could also be resulted from a general transcriptional
down-regulation induced by the double stranded structure of siRNA
without involving speciﬁc target mRNA cleavage [12,13]. Therefore,
it is critical to conﬁrm that an observed target gene expression
knockdown has occurred through the siRNA-induced mRNAB.V. This is an open access article ucleavage. However, the precise cleavage sites on the siRNA-targeted
mRNA were not commonly identiﬁed and conﬁrmed in current lit-
eratures. Such efforts might partly been hampered by technical
difﬁculties in detecting and verifying the cleaved mRNA inter-
mediates and end products. New biological and biochemical meth-
ods are much needed to efﬁciently and accurately identify inter-
mediates and end-products resulted from the siRNA action in mul-
ticellular organisms under physiological conditions. In this study, we
used a novel stem-loop array RT-PCR (SLA-RT-PCR) assay to accu-
rately identify siRNA-mediated target mRNA cleavage sites by efﬁ-
ciently detecting the cleaved 5′-fragments of target mRNAs under
the physiological condition in human cells. We used the synthetic
siRNAs with an ectopically expressed mRNA target templates as
testing models, and the wild-type (wt) and mutant (mut)-sequence
speciﬁc siRNAs to endogenous target mRNA to evaluate the sensi-
tivity, speciﬁcity, and efﬁcacy of the SLA-RT-PCR assay for detecting
siRNA-mediated mRNA cleavage in mammalian cells under physio-
logical conditions. Our results demonstrated the great potential and
broad applications of using the SLA-RT-PCR assay to systematically
detect intermediates and end products of target mRNA cleavage in
multi-cellular organisms under physiological conditions.2. Materials and methods
2.1. Cell culture and siRNA treatment
The human non-small cell lung cancer cell (NSCLC) lines H1299
(KRAS-wild type) and H358 (KRASG12C (GGT to TGC)-mutant)
were obtained from American Type Culture Collection (ATCC).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic representation of detection siRNA-mediated target mRNA cleavage activities by SLA-RT-PCR assay. RNA-induced silencing complex (RISC) cleaves target
mRNA into two distinct fragments: a 5′ fragment with a 3′ hydroxyl group, and a 3′ fragment with a 5′ phosphate. (A) SLA-RT-PCR assay includes two steps: SLA-RT and PCR.
SLA-RT efﬁciently detects the cleaved 5′-fragments of target mRNA. PCR is preceded with a pair of forward and reverse primer that contains an antisense sequence
complementary to the 5′-end of target mRNA and to the 3′-end of the stem loop of RT-primer. (B) SLA-RT-Primer design and the synthetic RNA44 RNA template sequences
for detection and veriﬁcation of 3′ ends of synthetic small nucleolar RNU44 RNA by SLA-RT-PCR. The predicted full length RNU44 RNA sequences with 3′ end sequences
(underlined) targeted by 3′-SLA-RT primers are shown. (C) Detection and veriﬁcation of 3′ ends of RNU44 RNA by 3′-SLA-RT primers. SLA-RT-PCR products were detected by
agarose gel electrophoresis (upper panel) and relative band intensity was shown in lower panel.
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with 10% fetal bovine serum in an atmosphere of humidiﬁed air
containing 5% CO2. Cells were grown in a 6-well plate to 80%
conﬂuence and then transfected with siRNA. The transfection was
performed using the transfection agent DharmaFECT 1 according
to the manufacturer’s protocols (Dharmacon).
2.2. Plasmid construction
The siRNA-targeted mRNA sequences were directly derived
from tumor suppressor gene TUSC2 [14]. The plasmid vector
containing the siRNA target sequence was constructed by insertingthe siRNA targeting sequence into the reporter GFP Plasmid
(Fig. 3A). All sequences in plasmid constructs were conﬁrmed by
automated DNA sequencing.
2.3. Synthesis of materials
The small RUN44 RNAs with a predicted sequence of sixty-six
nucleotides (Fig. 2A) were synthesized using commercial source
(Sigma) and puriﬁed by polyacrylamide gel electrophoresis
(PAGE). The puriﬁed RUN44 RNA was used as a RNA template to
evaluate SLA-RT-PCR for detection and veriﬁcation of the 3′ end of
RUN44 RNA. All SLA-RT primers and PCR primers and siRNAs were
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sequences were described and illustrated in individual ﬁgures.
2.4. RNA isolation
Cells were grown on 6-well plates and approximately 2106
cells were used to isolate the total RNA using the TRIzol reagent
(Life Technologies) and the additional phenol/chloroform extrac-
tion was performed before ethanol precipitation according to the
manufacturer's protocol. The isolated total RNA was stored in 70%
ethanol at80 °C. The puriﬁed total RNA was dissolved in RNase-
free water for SLA-RT-PCR reactions.
2.5. Stem-loop array reverse transcriptase reaction (SLA-RT)
RNA samples were brieﬂy treated with 0.04U/ml RNase-free
DNase I. RNA was reversed transcribed using the High Capacity
Reverse Transcription kit (Life Technologies) in combination with
an array of stem-loop RT primers. The 20 ml of RT reaction con-
tained 50 ng of total RNA, 51012 mol of SLA-RT primer, 2 ml ofFig. 2. Sensitivity of the SL-RT-PCR assay. The SL-RT-PCR reactions were performed using
RNA templates over ﬁve orders of magnitude from 101 to 103 molecules and RT-PCR pro
RT-PCR assay. From 101 to 105 molecules of synthetic RNA templates were detected
electrophoresis (C) and corresponding liner regression plots of the RNA template input10RT buffer, 1 ml of Multiscribe Reverse Transcriptase, and 0.8 ml
of 100 mM dNTPs. To increase reverse transcription efﬁciency, a
pulsed RT reaction was performed on a DNAEngine Peltier Thermal
Cycler (Bio-Rad) with 60 cycles at 20 °C for 1 min and 37 °C for 1 s,
followed by 60 cycles at 18 °C for 1 min and 37 °C for 1 s, and a
ﬁnal cycle at 37 °C for 30 min, 42 °C for 20 min, and extension at
85 °C for 10 min, and then held at 4 °C.
2.6. 5′RACE
5′-RACE was performed using the 5′ RACE System for Rapid
Ampliﬁcation of cDNA Ends, version 2.0 kit (Invitrogen, Life Tech-
nology) with the manufacturer's instructions. Brieﬂy, ﬁrst-strand
cDNA was synthesized using a kras -speciﬁc primer (5′-TCA-
CATTTATTTCCTACTAGGACCATA-3′). The original mRNA template
was removed by treatment with RNase Mix. Unincorporated dNTPs,
GSP1, and proteins were separated from cDNA using a S.N.A.P.
Column. A homopolymeric tail was then added to the 3′-end
of the cDNA using TdT and dCTP. PCR was ampliﬁed by GSP2 primer
(5′-GTACATCTTCAGAGTCCTTAACTCTT-3′) and deoxyinosine-two SL-RT primers (P1 and P2) (A). Known concentrations of input synthetic RNU44
ducts were analyzed by agarose gel electrophoresis (B). (C) Dynamic range of the SL-
by using SLA-RT-PCR assay and SL-RT-PCR products were analyzed by agarose gel
vise the relative output of SL-RT-PCR products are presented (D).
Fig. 3. Detection of siRNA cleavage sites by SLA-RT-PCR assay. (A) Sequences of siRNA and its target mRNA and SLA-RT primers. The sequences of the SLA-RT primer #16
anticipated for most efﬁciently detecting the predicted siRNA cleavage site on target RNA template is underlined. (B) The predicted size of SLA-RT-PCR fragment ampliﬁed by
SLA-RT primer #16. (C) Detection of siRNA cleavage site in H1299 cells co-transfected with siRNA- and target RNA expressing plasmids by SLA-RT-PCR. (D) DNA sequencing
conﬁrmation of the siRNA cleavage site and the cleaved RNA fragment detected by SAL-RT-PCR.
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kit manual: 1 cycle of 94 °C for 4 min, then 35 cycles of 94 °C
for 30 s, 55 °C for 30 s 72 °C for 1 min, and ﬁnal extension of 72 °C
for 10 min. From this reaction, 10 ml was analyzed on a 1.5% agarose
gel.2.7. Polymerase chain reaction (PCR)
Each cDNA sample generated from the SLA-RT reaction was
diluted 500-fold. Twenty μl of PCR mix contain 1 μl of diluted RT
products, 2 μl of 10 standard PCR buffer, 0.8 μl of 10 mM dNTPs,
J. Lin et al. / Biochemistry and Biophysics Reports 6 (2016) 16–23200.5 μl of 100 mM MgSO4, 0.2 μl of Taq polymerase, 1 μl of 10 μΜ
of forward primer and 1 μl of 10 μΜ of reverse primer. PCR re-
actions were conducted at 95 °C for 5 min, followed by 35 cycles at95 °C for 15 s, 61 °C for 30 s, and 37 °C for 30 s, and a
ﬁnal extension at 72 °C for 10 min, on DNAEngine Peltier Thermal
Cycler.
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U6: sense primer, 5′-CCTGGATGATGATAAGCAAATGC-3′, anti-
sense primer, 5′-GTGCGGGTCCGAGGTATTC-3′.
TUSC2: sense primer, 5′-CGGCATGGACGAGCTGTACAAGTA-3′,
antisense primer, 5′-GTGCGGGTCCGAGGTATTC-3′.
KRAS: sense primer, 5′-GAAGGTGGCGGCGGCTCG-3′, antisense
primer, 5′-GTGCGGGTCCGAGGTATTC-3′.
PCR products sequence analysis was performed on an ABI 3730
DNA sequencer by DNA Analysis Core Facility at MD Anderson
Cancer Center.
2.8. Agarose gel electrophoresis
SLA-RT-PCR products were analyzed by 1.5% agarose gel elec-
trophoresis in 1Tris-Borate-EDTA (TBE) buffer containing 89 mM
of Tris Base and 89 mM of Boric Acid. Electrophoresis was per-
formed at 100 V for 60 min. Gel was stained in ethidium bromide
bath for 10 min prior to visualization using a UV transilluminator.3. Results
3.1. Detection and veriﬁcation of 3′ ends of synthetic RNU44 RNA by
SLA-RT-PCR
We adopted a novel SLA-RT-PCR technique, originally developed by
Chen et al. [15], to systematically verify and detect intermediate mRNA
fragments cleaved by siRNAs. This approach accurately identiﬁed un-
ique nucleotide ends generated by the siRNA-mediated target cleavage
activities in human cells. The principle of works, the experimental
design, and assay procedures are illustrated in Fig. 1A. The SLA-RT-PCR
assay includes two steps: SLA-RT and PCR. SLA-RT primers comprised
two unique sequence components: a short stretch of 6-base single-
stranded nucleotides at the 3′ end of the primer sequences that are
complementary to the 5′-terminal sequences of the target mRNA, and
a double stranded stem at the 5′ end that forms a stem-loop to
function as a forceps to stabilize the secondary structure of the primer.
The terminal sequences of the siRNA-cleaved target mRNA fragments
are speciﬁcally recognized by a six-nucleotide complementary exten-
sion at the 3′ends of the RT-primer array, which could efﬁciently
prime the reverse transcription of the cleaved mRNA fragments into
cDNAs. The uses of an array of stem-loop RT primers allow accurate
recognition and veriﬁcation of unique ends of the mRNA fragments
processed by endonucleases. If the SLA-RT primers have no perfect
match, on both the length and the base, to the sequence of the 3′ or 5′
end of the mRNA fragment the efﬁciency of RT reaction would have
been dramatically reduced. The subsequent PCR is preceded with a
pair of forward and reverse primer that contains an antisense se-
quence complementary to the 5′-end of mRNA and to the 3′-end of
the stem loop of RT-primer, respectively. The abundance of the tran-
script-speciﬁc SLA-RT-PCR amplicons represents the distribution of
cleaved RNA fragments and is determined by agarose gel electro-
phoresis. The success of SLA-RT-PCR relies deeply on the differential
priming efﬁciency between matched and mismatched SLA primersFig. 4. Detection of the cleavage site on endogenous mutant KRASG12C (GGT to TGT) mRNA
design of SLA-RT primers for detecting the cleavage site on the mutant KRASG12C (GGT to
was anticipated to most efﬁciently detect the predicted siRNA cleavage site on mutant K
KRAS mRNA in the wt-KRAS-containing H1299 cells (B) and the mutant KRASG12C (GGT to T
lipofectamine, respectively. After 48 h transfection, total RNAs were isolated and SLA-RT
detected by agarose gel electrophoresis in H358 (KRAS-mut) cells but not in H1299 (KRA
cleavage site in H358 cells were conﬁrmed by automated DNA sequencing. The SLA-RT pr
RACE assays in detection of KRASG12C (GGT to TGT)-siRNA cleaved KRAS mRNA fragments and
as described in (C) was used as the RNA template for RT reactions initiated by both the
electrophoresis and shown in Lane 1, the positive control for 5′RACE method, Lane 2, th
assay with SLA-RT primer #11 as described in (A). The KRASG12C (GGT to TGT)-siRNA-cleave
interpretation of the references to color in this ﬁgure legend, the reader is referred to twith the cleaved mRNA fragments at 3′ termini. Thus, the priming
efﬁciency by SLA-RT-primers is determined by the perfect match,
mismatch, overhang, and gap presented in SLA-RT-primer: mRNA
target hybrids.
We ﬁrst used the synthetic small RUN44 RNA as a model system
to evaluate SLA-RT-PCR for detection and veriﬁcation of the 3′ end of
RUN44 RNA fragments (Fig. 1B). The RNU44 is a member of abundant
intronic small-nucleolar RNAs that are frequently used as reference
genes for measuring endogenous miRNA expression. We designed
eleven SLA-RT-primers (Fig. 1B) and performed SLA-RT-PCR reactions
using the PAGE-puriﬁed synthetic RNU44 RNA as a template to
characterize effects of mismatch, overhang and gap in primer/target
hybrids on SLA-RT priming ﬁdelity and efﬁciency. Eleven SLA-RT-
primers that differed by at least one nucleotide at 5′ or 3′ end of
probe were used to reverse transcript the same RUN44 RNA tem-
plate. The resultant SLA-RT-PCR amplicons were analyzed by agarose
gel electrophoresis (Fig. 1C). As expected, the SLA-RT primer (Primer
1) with the perfect match to the 3′ end of RNU44 template suc-
cessfully initiated reverse transcription of template RNA with the
highest efﬁciency (Fig. 1C, Lane 1). However, those probes with 2 or
more nucleotide mismatches failed to initiate cDNA synthesis even
with up to 500 copies of templates incubated. The RT-priming efﬁ-
ciency for probes with single nucleotide mismatch varied with the
location of mismatches. The priming efﬁciency of SLA-RT primers
was markedly reduced by the mismatch at the 3′-ends of probes but
less sensitive to the mismatch at 5′-sites of probes (Fig. 1C, Lane
7 compared to Lane 1). A similar trend was also observed with a
single nucleotide hangover at 5′ end of the probe as demonstrated in
Fig. 1C, Lane 11. The priming ﬁdelity of the SL-RT primer was fully
restored with a two-nucleotide overhang, as shown in Fig. 1C, Lane
10. These results indicated the high speciﬁcity of the designed SLA-RT
primers to the 3′ end sequence of RNA fragments.
3.2. The dynamic range and sensitivity of SLA-RT-PCR
To evaluate the dynamic range and sensitivity of the SLA-RT-PCR
assay, we compared the SLA-RT-priming efﬁciency between a gap-
generating SLA-RT-primer (P1) and a matched SLA-RT-primer (P2) on
the synthetic RNU44 RNA template (Fig. 2A). The gap generated be-
tween the RNA template and the primer P1 effectively prevented the
reverse transcription of the mismatched template, whereas the RNA
template-matched probe P2 could efﬁciently initiate RT and detect
RNA templates at concentrations as low as 10 copies RNA (Fig. 2B).
Furthermore, we determined the dynamic range and sensitivity of
SLA-RT-PCR assay using SLA-RT primer P2 with the PAGE-puriﬁed
synthetic RNU44 template in a series of dilution over a range of 7 or-
ders of magnitude from 101 to 105 copies (Fig. 2C). The SLA-RT-PCR
assay showed an excellent linear output of PCR products corre-
sponding to the RNA template copies over a dynamic detection range
at lease of ﬁve orders of magnitudes (from 10 to 105 copies) and de-
monstrated an extremely high sensitivity that is capable of detecting
as few as 10 template molecules in SLA-RT-PCR reactions (Fig. 2D).
Together, these results clearly demonstrated the speciﬁcity and high
sensitivity of the SLA-RT-PCR assay.mediated by the mutant-speciﬁc siRNA with SLA-RT-PCR in NSCLC cells. (A) The
TGT) mRNA targeted by mutant-speciﬁc siRNA. The SLA-RT primer #11 (underlined)
RAS mRNA template. Detection of the siRNA-targeted cleavage on the endogenous
GT)-containing H358 cells (C) transfected with KRASG12C (GGT to TGT)-speciﬁc siRNA by
-PCR was performed. The predicted mRNA cleavage fragments (202 bp) should be
S-wt) cells. (D) The KRASG12C (GGT to TGT)-siRNA cleaved KRAS mRNA fragments and
imer probe #11 was marked by red underline. (E) Comparison of SLA-RT-PCR and 5′
cleavage site in H358 cells. The same amount of total RNAs isolated from H358 cells
5′RACE and the SLA-RT-PCR assays. The PCR products were analyzed by agarose gel
e mut-KRAS-mRNA-speciﬁc 5′RACE, and Lane 3, the mut-KRAS-speciﬁc SLA-RT-PCR
d mRNA fragments (202 bp) detected by SLA_RT-PCR is indicated by the arrow. (For
he web version of this article.)
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sites by SLA-RT-PCR
In order to evaluate the potential of SLA-RT-PCR assay in
identifying siRNA targets and determining its mechanism of ac-
tion, we used a synthetic siRNA and ectopically expressed artiﬁcial
mRNA template as a model system to precisely detect and verify
the intermediates and end products of the siRNA activity in
mammalian cells under physiological conditions. It has been
shown that mammalian siRNAs silence gene expression by cleav-
ing their target mRNAs for sequential degradation [10]. The siRNA
cleavage site on the mRNA target is usually located in the middle
of the region spanned by the siRNA:mRNA duplex, following a
canonical pattern of 10 bp from the 5′-end of siRNA in the RISC
[11]. The RISC-associated argonaute 2 (AGO 2) cleaves target
mRNA into two distinct fragments: a 5′ fragment with a 3′ hy-
droxyl group, and a 3′ fragment with a 5′ phosphate [16–18]. The
siRNA and the siRNA-targeted mRNA template expression plasmid
were co-transfected into human non-small cell lung cancer
(NSCLC) H1299 cells (Fig. 3). The siRNA and its target mRNA se-
quences, the predicted siRNA cleavage site, and the designed set of
twenty-eight SLA-RT primers for detection of the potential siRNA-
directed target RNA cleavage sites were illustrated in Fig. 3A and B.
The siRNA-mediated cleavage site on the mRNA target was pre-
cisely detected by the SLA-RT-PCR in the middle of siRNA target
region at the predicted position “G”, which is 10 bp from the 5′-
end of siRNA duplex, as shown in Fig. 3C and indicated by arrow.
The identity of the SLA-RT-PCR products was further veriﬁed by
DNA sequencing (Fig. 3D). These results clearly demonstrated the
potential applications of SLA-RT-PCR in identifying authentic siR-
NA targets by precisely detecting and verifying the cleavage sites
on target mRNAs mediated by siRNAs in mammalian cells.
3.4. Detection of siRNA-mediated cleavage activities on endogenous
mRNA targets
To further demonstrate the utility and speciﬁcity of SLA-RT-PCR
in detection the siRNA-mediated cleavage sites on endogenous
mRNA targets in human cells under physiological conditions, we
determined cleavage activities mediated by synthetic siRNAs that
speciﬁcally target the wild-type and the mutant sites, respectively,
on the endogenous KRAS mRNA sequences in human NSCLC
H1299 (KRAS-wt) and H358 (KRASG12C (GGT to TGT)-mut) cells
(Fig. 4). The mut-KRAS-speciﬁc siRNAs (Fig. 4A) were transfected
into H1299 and H358 cells by DharmaFect1 transfection reagent
and total RNAs were isolated 48 h after transfection. A set of SLA-
RT primers covering entire siRNA complementary and the im-
mediately adjacent 5′- and 3′ sequences (Fig. 4A) on wt-KRAS
(Fig. 4B) or mut-KRAS (Fig. 4C) mRNA sequences were used to
detect and verify the predicted cleavage site as indicated by arrow
(Fig. 4A). The siRNA-cleaved KRAS mRNA fragments with a pre-
dicted size of 202 bp could be detected by agarose gel electro-
phoresis only in mut-KRASG12C (GGT to TGT)-containing H358 cells
(Fig. 4C) but not in wt-KRAS-expressing H1299 cells (Fig. 4B)
transfected by the mut-KRAS-siRNA. The KRASG12C (GGT to TGT)-
siRNA cleaved mut-KRAS mRNA fragments and cleavage site in
H358 cells were conﬁrmed by automated DNA sequencing
(Fig. 4D).
To further validate the utility, speciﬁcity, and sensitivity of SLA-
RT-PCR assay in detection of siRNA-cleavage site and cleaved 5′-
mRNA fragments, we performed a parallel comparison between
the SLA-RT-PCR and the 5′RACE (Invitrogen, Life Technologies)
methods (Fig. 4E), using the same total RNAs isolated in H358 cells
transfected with KRASG12C (GGT to TGT)-siRNA as described in Fig. 4C
as the template for RT reactions respectively initiated by the SLA-
RT and 5′RACE-RT primers speciﬁc to endogenous KRAS mRNAtranscripts. The predicted 5′RACE product was clearly detected by
the positive control provided in 5′RACE kit (Fig. 4E, Lane 1) but no
5′RACE products were detected using KRAS-speciﬁc RT primer
(Fig. 4E, Lane 2). The predicted KRASG12C (GGT to TGT)-siRNA-cleaved
mRNA fragments (202 bp) was clearly detected by SLA_RT-PCR
using the mutant KRAS-speciﬁc SLA-RT primer #11 (A), as simi-
larly shown in (C) and indicated by the arrow. These results de-
monstrated the sensitivity and advantages of SLA-RT-PCR assay in
detection of speciﬁc sites and 5′-fragments cleaved by siRNA ac-
tivities under physiological conditions over the conventional
methods such as the 5′RACE.4. Discussion
siRNA has been shown to be a powerful tool for analyzing gene
function and developing novel therapeutic drugs targeting speciﬁc
disease-causing or cancer-driving genes by silencing expression of
a speciﬁc gene and encoded protein product [4]. However, for the
successful application of siRNA as a therapeutic for human disease,
one of most critical questions need to be answered in the clinical
practice is to detect and conﬁrm whether the designed siRNA
therapeutic hits its predicted gene target. This question can be
effectively addressed by accurately detecting the siRNA cleavage
sites and cleaved products of the target mRNA. However, such
efforts might partly be hindered by technic difﬁculties in detecting
and verifying speciﬁc cleavage mRNA sites and the cleaved mRNA
intermediates and end products.
Traditional RT-PCR cannot detect mRNA transcript termini and
intermediates generated by various cellular processes and biolo-
gical activities, which are important for understanding the biolo-
gical signiﬁcance of mRNA polymorphisms and mRNA function-
alities. These mRNA variants might reﬂect the difference of
abundances between full length transcripts and shortened tran-
scripts, produced by partial degradation, modiﬁcation or cleavages
of transcripts through various RNA editing mechanisms, including
siRNA targeted mRNA cleavages. Currently, 5′-RACE (rapid ampli-
ﬁcation of cDNA ends), 3′-RACE, cRT-PCR (circulative RT-PCR) and
Next Generation of Sequencing (NGS) are a few technologies to
fulﬁll these needs for mRNA cleavage activities through RNA self-
circulation or adapter addition by RNA ligase [19,20]. However,
those technologies have their corresponding limits in sensitivity,
accuracy, and cost- and time-efﬁciency. Moreover, the inevitable
use of RNA ligase in some of those methods result in enzymatically
biased interpretation in the distribution of RNA terminus and
signiﬁcantly reduced their detection sensitivity and accuracy, as
we demonstrated in parallel comparison of the SLA-RT-PCR and 5′
RACE methods.
In this study, we have evaluated the sensitivity and speciﬁcity
of SLA-RT-PCR method for identifying siRNA-mediated target
mRNA cleavage sites by accurately detecting the termini of siRNA-
cleaved target mRNA fragments on both the ectopically expressed
in human cells under physiological conditions. Our results de-
monstrated a great differential RT-priming efﬁciency between
matched and mismatched SLA-RT-primers to the 3′-termini of
siRNA-cleaved target mRNA fragments. This method is extremely
sensitive, allowing detection of RNA fragments as few as 10 tem-
plate copies with a linear correlation up to 5 orders of magnitudes
with primers tested. Although the liner correlation could be al-
tered by the different compositions among SLA-RT-primers, which
could potentially alter the Tm (melting temperature) of SAL-RT
primers, the intensity of the individual SLA-RT-PCR amplicon was
principally determined by the RNA fragment abundance and the
base-stacking enhancement of perfectly matches between RNA
terminal and SLA-RT-primer sequences. The high GC- or AT- rich
sequence contents at the 3′-termini of the cleaved target miRNA
J. Lin et al. / Biochemistry and Biophysics Reports 6 (2016) 16–23 23fragments may affect the priming efﬁciency of SLA-RT, however,
our testing results with varied base compositions at 3′-termini of
synthetic mRNA templates and corresponding matched or un-
matched SLA-RT primers demonstrated that the priming efﬁciency
was more depended on the degree of base matches than the
content of bases. The SLA-RT-PCR could potentially be used to
more quantitatively determine the cleaved mRNA products by
real-time PCR with probes speciﬁc to the predicted PCR amplicons.
This method could also be modiﬁed to detect the cleaved mRNA
fragments with unknown ends such as 3′-urydylation, tailing, and
trimming by modifying the SLA-RT primers with “U-tract” and
randomizing 6-nt short stretch at the 3′-end of SLA-RT primers.
Due to the high sensitivity and speciﬁcity of SLA-RT-PCR as de-
monstrated, this method is principally sufﬁcient and capable to
detect the precise siRNA cleavage site on the targeted mRNA by
taking advantages of the high ﬁdelity of SLA-RT primers in re-
cognizing speciﬁc ends of RNA fragments generated in RISC and
efﬁciently capturing an immediate and unmodiﬁed cleavage
fragment from a population of speciﬁc-siRNA-cleaved mRNA in-
termediates and end products at any given time under a physio-
logical condition. By incorporating randomized stem-loop-array
RT primer sequences and in combination with targeted deep se-
quencing, the modiﬁed SLA-RT-PCR method can be used as a
“high-throughput” assay to capture all potential mRNA cleavage
sites and cleaved fragments by “on-target” and “off-target” activ-
ities of a speciﬁc siRNA.
Our results demonstrated the great potential and broad appli-
cations of using the SLA-RT-PCR as a sensitive, speciﬁc, and cost-
efﬁcient tool to identify authentic siRNA-cleavage sites in multi-
cellular organisms under physiological conditions. SLA-RT-PCR can
efﬁciently detect and conﬁrm whether the designed siRNA ther-
apeutic hits its predicted gene target and could be a useful tool for
facilitating the application of siRNA-based therapeutics in human
diseases.Conﬂict of interests
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